TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00412750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT)
Description: 600 mg orally once daily for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT)
Description: 600 mg orally once daily for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a
Description: 180 μg subcutaneous injection once a week for 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alpha-2a
Description: 180 μg subcutaneous injection once a week for 52 weeks.
Study: NCT00006565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA Air Cleaner
Description: Placement of two active HEPA air cleaners in the homes of children

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Filtration Unit
Description: Placement of inactive filtration unit in the homes
Study: NCT01977781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Sodium Succinate
Description: Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
Study: NCT01864278

Intervention type: DEVICE
Intervention: Lutonix Drug Coated Balloon
Description: Subject will receive treatment with the Lutonix Drug Coated Balloon
Study: NCT00246532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo tablets.
Study: NCT01084070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early oral feeding
Description: Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Care
Description: They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
Study: NCT01084187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: vardenafil 20 mg on demand or vardenafil daily or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vardenafil
Description: vardenafil 20 mg on demand or vardenafil daily or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: vardenafil 20 mg on demand or vardenafil daily or placebo
Study: NCT02600507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone (ITI-007)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone (ITI-007)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01932957

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparotomy arm
Description: Laparotomy as standard treatment for ruptured ectopic pregnancy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy arm
Description: Laparoscopy as treatment for ruptured ectopic pregnancy
Study: NCT02485145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A/B
Description: This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo, which consists of the VersaPro cream, will be utilized in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo, which consists of the VersaPro cream, will be utilized in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/A
Description: This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
Study: NCT01082185

Intervention type: DEVICE
Group type: OTHER
Intervention: Ovation Abdominal Stent Graft System
Description: Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
Study: NCT01272310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin
Description: HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is \< 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is \>= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening).
Study: NCT00896675

Intervention type: OTHER
Intervention: proteomic profiles
Description: blood samples analysis

Intervention type: OTHER
Intervention: proteomic profiles
Description: blood samples analysis
Study: NCT02269527

Intervention type: OTHER
Group type: OTHER
Intervention: Live music
Description: Providing 1-hour live music 5 days/ week.
Study: NCT02115464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus Chemo-radiotherapy
Description: Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-radiotherapy
Description: Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
Study: NCT00643695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based walking program
Description: The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational intervention
Description: Participants in the control group will receive a packet of information regarding hepatitis C
Study: NCT01781221

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Bio's GRAFT Natural Bovine Bone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss xenograft
Study: NCT03807713

Intervention type: DEVICE
Group type: OTHER
Intervention: Minimally Invasive Ponto Surgery
Description: Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implants in patients indicated and counselled for Bone Anchored Hearing Systems.
Study: NCT00971945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
Study: NCT03354663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiCath SE
Description: Ablation to achieve pulmonary vein isolation.
Study: NCT02836067

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Smoking cessation counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Smoking Cessation drugs
Description: Medication to aid smoking cessation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy
Description: Bronchoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy
Description: Bronchoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draw
Description: Screening and research blood draws

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draw
Description: Screening and research blood draws

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Behavioral questionnaires

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Behavioral questionnaires
Study: NCT00554125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
Study: NCT04720326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Pill
Description: Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus capsule
Description: Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
Study: NCT01535781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical syringe and drip used as in the intervention, to ensure blinding.
Study: NCT01158482

Intervention type: PROCEDURE
Intervention: IVC Filter Placement or Retrieval
Description: An IVC Filter will be placed or removed using endovascular techniques.
Study: NCT02417272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical treatment of cervical degenerative disc disease (CP ESP®)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical treatment of cervical degenerative disc disease (Axelle®)
Description: Axelle®
Study: NCT01525004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose trivalent inactivated influenza vaccine
Description: 0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose trivalent inactivated influenza vaccine
Description: 0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
Study: NCT01378312

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AERAS 402
Description: 0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
Study: NCT02303379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Endurance Training
Description: Endurance training with constant work load 31min at 65-75% Hrmax

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Endurance Training
Description: Endurance training with constant work load 31min at 65-75% Hrmax

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pyramid Training
Description: One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyramid Training
Description: One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
Study: NCT02979665

Intervention type: DRUG
Intervention: Ranibizumab Ophthalmic
Description: Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME).
Study: NCT01526902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A / PC 1-D MF
Description: Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A / PC 1-D MF
Description: Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B / Air Optix MF
Description: Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B / Air Optix MF
Description: Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
Study: NCT04077658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartMath
Description: HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HeartMath
Description: HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Standard of Care Migraine Treatment
Study: NCT02859935

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Screening and feedback
Description: Screening via questionnaires on mental health problems and feedback on the questionnaires
Study: NCT05244265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: The 8 week (plus one-day retreat) manualized MBSR program according to the manual (Kabat-Zinn, 1982).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Different interventions and support in outpatient and other services.
Study: NCT00812214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3 mg tablet every night at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet every night at bedtime
Study: NCT01069562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional control
Description: The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed loop control
Description: The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
Study: NCT02482454

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Study: NCT02716610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH 69 U (low)
Description: inhaled human insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH 69 U (high)
Description: inhaled human insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH 139 U
Description: inhaled human insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH 208 U
Description: inhaled human insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIS 18 U
Description: subcutaneous insulin lispro
Study: NCT04451915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: late management strategy
Description: late management strategy of GDM defined as no intervention until GDM screening at 24-28 weeks. Between 24-28 weeks gestation, a 75-g OGTT will be done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early management strategy
Description: early management of GDM defined as intensive metabolic treatment. Intensive treatment involved the following multidisciplinary approach: lifestyle defined by diet and exercise intervention according to the French guidelines
Study: NCT04019132

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle function test
Description: Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle function test
Description: Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle function test
Description: Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle function test
Description: Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
Study: NCT04693000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment
Description: An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
Study: NCT01656031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study: NCT00782457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RECTAL CANCER RESECTION

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RECTAL CANCER RESECTION
Study: NCT03673683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SANDWICH protocol
Description: A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual sedation and weaning management that is not protocol based
Study: NCT02944630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Individual psychotherapy
Study: NCT02492503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and carboplatin
Description: Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and carboplatin
Description: Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
Study: NCT02074852

Intervention type: OTHER
Intervention: Foley urethral catheter

Intervention type: OTHER
Intervention: Foley urethral catheter